News

#EULAR2018 – Combo of TNF Inhibitors, NSAIDs Fight Long-Term Radiographic Progression of AS

Use of nonsteroidal anti-inflammatory drugs (NSAIDs) in addition to tumor necrosis factor (TNF) inhibitors provides stronger long-term protective effects in patients with ankylosing spondylitis, according to recent clinical trial results. The combo therapy prevented radiographic progression of the disease significantly during a four-year period compared to NSAIDs or…

#EULAR2018 – Latest Clinical Data on Cosentyx Reinforces Its Potential to Treat Ankylosing Spondylitis

Latest clinical data on Cosentyx (secukinumab) demonstrates its long-term potential to prevent radiographic progression and improve the quality of life of patients with ankylosing spondylitis. Several relevant studies were presented recently at 2018 Annual European Congress of Rheumatology (EULAR), held in Amsterdam, The Netherlands. Cosentyx is a specific…

Social Media Allows Glimpse into AS Patients’ Thoughts on Biologics

Social media data has allowed scientists to examine ankylosing spondylitis patients’ knowledge, attitudes, and beliefs regarding biologic therapies. The study, “Patients’ Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights from a Large-Scale Survey of Social Media Platforms,” was published in the journal Arthritis Care &…

Lupin Seeks EU Marketing Approval for YLB113, Etanercept Biosimilar, for Ankylosing Spondylitis

The European Medicines Agency has accepted for review Lupin‘s marketing authorization application for YLB113, a biosimilar of etanercept that is marketed by Amgen under the brand name Enbrel. YLB113’s application is for the treatment of ankylosing spondylitis, axial spondyloarthritis, and non-radiographic axial spondyloarthritis, as well as rheumatoid and psoriatic arthritis…